DENVER—September 8, 2021—The International Association for the Study of Lung Cancer today named Michael Boyer, MBBS, FRACP, PhD, as 2021 recipient of the Adi F. Gazdar IASLC Merit Award. The announcement was made during the IASLC 2021 World Conference on Lung Cancer.
In 2019, the IASLC Board of Directors unanimously voted to elevate its recognition of Dr. Adi F. Gazdar to one of its highest honors by renaming the IASLC Merit Award for Dr. Gazdar. The Adi F. Gazdar IASLC Merit Award proudly recognizes and honors Dr. Gazdar’s lifelong dedication to lung cancer research through his pioneering work in molecular pathology. The recipient of the annual Adi F. Gazdar IASLC Merit Award is chosen by the IASLC Executive Committee and is announced and recognized at the annual World Conference on Lung Cancer. Michael Boyer, MBBS, FRACP, PhD, is the chief clinical officer for The Lighthouse Chris O’Brien, a not-for-profit comprehensive cancer center in Sydney, Australia. Previously, he served as the director of Cancer Services for the Sydney South West Area Health Service. He also has an appointment as a clinical professor within the Central Clinical School of the University of Sydney. He is the co-chair of Medical Oncology and Thoracic Oncology at Lifehouse.
In 2010, Dr. Boyer was made a member of the Order of Australia for his work as an educator, as a clinical trials researcher, and for his involvement in the development of integrated care facilities for people suffering with cancer. Dr. Boyer continues to be actively involved in research, focusing on the testing of new anticancer drugs for the treatment of lung cancer. Dr. Boyer has a Bachelor of Medicine and Bachelor of Surgery from the University of Sydney and a doctorate in Cell Biology from the University of Toronto. He has been involved in the Lifehouse project from the very beginning, alongside his friend and colleague Chris O’Brien, and remains dedicated to helping guide the clinical direction of the facility.
“I see my role at Lifehouse as an amazing opportunity to help those with cancer and their families, while at the same time working on research that will eliminate cancer as a problem,” he said.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes nearly 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2021.iaslc.org/.